The Society of Toxicology (SOT) 52nd Annual Meeting (http://www.toxicology.org/ai/meet/am.asp) is the largest toxicology meeting and exhibition in the world, with an expected attendance of more than 7,300 scientists from around the globe. The SOT Annual Meeting is the venue for toxicologists to learn about the scientific advances that have taken place over the past 12 months.
For more information:
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/
Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Stellar Biotechnologies, Inc.
Executive VP, Corporate Development & Finance
Main +1 (805) 488-2800
Mark A. McPartland
Senior Vice President
Phone: 1 212-301-7130
Most Popular Stories
- Nelson Mandela Dies After Momentous Life
- Twitter Names Woman to Board
- NSA Tracks 5 Billion Cellphone Records a Day
- Nelson Mandela Dead at 95
- Pope Francis Says He'll Fight Child Sex Abuse
- Yemen Attack Kills 52
- Fast-Food Workers Want $15 an Hour
- W.H. Corrects Itself on Unclegate
- Roybal-Allard Tours Gordon Brush Plant
- Aspen Contracting Adding 300 Jobs